

Emmanuelle Waubant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/90000/publications.pdf>

Version: 2024-02-01

157
papers

25,356
citations

41323

49
h-index

8156

148
g-index

160
all docs

160
docs citations

160
times ranked

19546
citing authors

#	ARTICLE	IF	CITATIONS
1	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. <i>Neurology</i> , 2022, 98, .	1.5	15
2	Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1330-1339.	1.4	8
3	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 268-281.	2.8	39
4	Preventing Multiple Sclerosis: The Pediatric Perspective. <i>Frontiers in Neurology</i> , 2022, 13, 802380.	1.1	4
5	Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. <i>BMJ Neurology Open</i> , 2022, 4, e000215.	0.7	4
6	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1819-1824.	1.4	2
7	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS". <i>Annals of Neurology</i> , 2022, 91, 735-736.	2.8	0
8	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	12
9	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103829.	0.9	8
10	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1814-1822.	1.4	19
11	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 922-932.	1.4	5
12	A validation study for remote testing of cognitive function in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 795-798.	1.4	25
13	Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. <i>Lancet Neurology</i> , The, 2021, 20, 38-48.	4.9	90
14	Biosensor vital sign detects multiple sclerosis progression. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 4-14.	1.7	6
15	Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 711-715.	1.7	4
16	A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 811-824.	1.7	8
17	Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination. <i>Annals of Neurology</i> , 2021, 89, 1234-1239.	2.8	16
18	Incidence of Acute Disseminated Encephalomyelitis in China: First National Survey. <i>Neuroscience Bulletin</i> , 2021, 37, 761-762.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	4
20	Gut microbiome is associated with multiple sclerosis activity in children. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1867-1883.	1.7	21
21	Ethical considerations in the treatment of multiple sclerosis fatigue. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103129.	0.9	7
22	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	4.9	261
23	Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1079.	3.1	2
24	High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103253.	0.9	16
25	New onset myoclonus and encephalopathy in a woman with multiple sclerosis: Consider the medications. <i>Neuroimmunology Reports</i> , 2021, 1, 100020.	0.2	1
26	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. <i>Cell Reports Medicine</i> , 2021, 2, 100424.	3.3	26
27	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110590.	0.5	1
28	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2252-2269.	1.7	34
29	Paediatric multiple sclerosis: a lesson from TERIKIDS. <i>Lancet Neurology</i> , The, 2021, 20, 971-973.	4.9	4
30	Vitamin D genes influence MS relapses in children. <i>Multiple Sclerosis Journal</i> , 2020, 26, 894-901.	1.4	17
31	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis. <i>Journal of Child Neurology</i> , 2020, 35, 77-83.	0.7	5
32	The multiple sclerosis gut microbiota: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101427.	0.9	102
33	Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1476-1485.	1.4	18
34	Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses. <i>JAMA Neurology</i> , 2020, 77, 327.	4.5	60
35	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1938-1947.	1.4	18
36	Two-armed active comparator trials are unethical in paediatric multiple sclerosis – Commentary. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1474-1475.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Pediatric Multiple Sclerosis Severity Score in a large US cohort. <i>Neurology</i> , 2020, 95, e1844-e1853.	1.5	11
38	Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102398.	0.9	12
39	Improved relapse recovery in paediatric compared to adult multiple sclerosis. <i>Brain</i> , 2020, 143, 2733-2741.	3.7	45
40	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. <i>American Journal of Neuroradiology</i> , 2020, 41, 2219-2226.	1.2	14
41	Autoimmune Encephalitis in Children: A Case Series at a Tertiary Care Center. <i>Journal of Child Neurology</i> , 2020, 35, 591-599.	0.7	12
42	Do you believe in Gad?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102299.	0.9	2
43	The COVID-19 pandemic and the use of MS disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 102073.	0.9	153
44	Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 88, 42-55.	2.8	68
45	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGM study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 483-492.	0.9	26
46	The future of microbiome research in neuroinflammatory disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 102098.	0.9	0
47	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. <i>Journal of Clinical Investigation</i> , 2020, 130, 3467-3482.	3.9	109
48	Environmental and genetic risk factors for MS: an integrated review. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1905-1922.	1.7	165
49	A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 50-54.	0.9	18
50	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
51	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019, 15, e1007808.	1.5	48
52	mi RNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1053-1061.	1.7	10
53	Introducing the International Women in Multiple Sclerosis network. <i>Lancet Neurology</i> , The, 2019, 18, 521.	4.9	5
54	Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. <i>Nature Reviews Neurology</i> , 2019, 15, 441-445.	4.9	18

#	ARTICLE	IF	CITATIONS
55	Clinical trials of disease-modifying agents in pediatric MS. <i>Neurology</i> , 2019, 92, e2538-e2549.	1.5	62
56	Mind the gap. <i>Neurology</i> , 2019, 92, 698-699.	1.5	1
57	Consistent control of disease activity with fingolimod versus IFN β -1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 91, jnnp-2019-321124.	0.9	22
58	Pediatric glial fibrillary acidic protein meningoencephalomyelitis: A case report and review of the literature. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 148-152.	0.9	12
59	Puberty onset and pediatric multiple sclerosis activity in boys. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 184-187.	0.9	7
60	Subclinical Saccadic Eye Movement Dysfunction in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019, 34, 38-43.	0.7	7
61	Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls. <i>Multiple Sclerosis Journal</i> , 2019, 25, 644-652.	1.4	12
62	Ovarian aging is associated with gray matter volume and disability in women with MS. <i>Neurology</i> , 2018, 90, e254-e260.	1.5	41
63	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
64	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	1.4	101
65	Dietary factors and pediatric multiple sclerosis: A case-control study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1067-1076.	1.4	27
66	The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 161-165.	0.9	15
67	Genetic risk factors for pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1825-1834.	1.4	37
68	Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 28-33.	0.9	74
69	Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 550-552.	0.9	5
70	Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 64, 67-76.	0.8	16
71	Body mass index, but not vitamin D status, is associated with brain volume change in MS. <i>Neurology</i> , 2018, 91, e2256-e2264.	1.5	65
72	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1222-1228.	1.7	25

#	ARTICLE	IF	CITATIONS
73	Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1211-1221.	1.7	55
74	Urban air quality and associations with pediatric multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1146-1153.	1.7	29
75	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. <i>Neurology</i> , 2018, 91, e1778-e1787.	1.5	55
76	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 1017-1027.	13.9	237
77	Sex differences and subclinical retinal injury in pediatric-onset MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 447-455.	1.4	19
78	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. <i>Neurology</i> , 2017, 88, 826-831.	1.5	168
79	The gut microbiome in human neurological disease: A review. <i>Annals of Neurology</i> , 2017, 81, 369-382.	2.8	388
80	The "Field Hypothesis": rebound activity after stopping disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, A1-A2.	0.9	13
81	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. <i>Neurology</i> , 2017, 88, 1623-1629.	1.5	138
82	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. <i>Pediatrics</i> , 2017, 139, e20162838.	1.0	40
83	Examining the contributions of environmental quality to pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 164-169.	0.9	21
84	Genetic variation in the gene <i>LRP2</i> increases relapse risk in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 864-868.	0.9	21
85	Executive Functioning in Pediatric Multiple Sclerosis: Considering the Impact of Emotional and Psychosocial Factors. <i>Journal of Pediatric Neuropsychology</i> , 2017, 3, 206-217.	0.3	0
86	Clinical Reasoning: A 16-year-old girl with subacute weakness and sensory loss. <i>Neurology</i> , 2017, 88, e225-e229.	1.5	1
87	Characteristics of Children and Adolescents With Multiple Sclerosis. <i>Pediatrics</i> , 2016, 138, .	1.0	89
88	Gut microbiota in early pediatric multiple sclerosis: a case-control study. <i>European Journal of Neurology</i> , 2016, 23, 1308-1321.	1.7	260
89	Dietary salt intake and time to relapse in paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1350-1353.	0.9	58
90	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 897-907.	1.7	67

#	ARTICLE	IF	CITATIONS
91	Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 366, 229-233.	0.3	13
92	Clinical Reasoning: Left hemiparesis, ataxia, and optic neuritis in a child previously treated for pineoblastoma. <i>Neurology</i> , 2016, 86, e161-e165.	1.5	0
93	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 87-92.	0.9	58
94	Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. <i>JAMA Neurology</i> , 2016, 73, 790.	4.5	177
95	Biopsy-Supported Tumefactive Demyelination of the Central Nervous System in Children. <i>Journal of Child Neurology</i> , 2016, 31, 1528-1533.	0.7	9
96	Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation—Reply. <i>JAMA Neurology</i> , 2016, 73, 1376.	4.5	4
97	International Pediatric MS Study Group Global Members Symposium report. <i>Neurology</i> , 2016, 87, S110-6.	1.5	19
98	Environmental and genetic factors in pediatric inflammatory demyelinating diseases. <i>Neurology</i> , 2016, 87, S20-7.	1.5	37
99	Neurodegeneration and Remyelination in Multiple Sclerosis. , 2016, , 311-337.		2
100	Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents — NO. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1651-1653.	1.4	0
101	Genetic predictors of relapse rate in pediatric MS. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1528-1535.	1.4	23
102	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016, 86, 1437-1445.	1.5	48
103	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. <i>Journal of the Neurological Sciences</i> , 2016, 363, 153-157.	0.3	137
104	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1446-1453.	1.5	64
105	Clinical features of neuromyelitis optica in children. <i>Neurology</i> , 2016, 86, 245-252.	1.5	100
106	Longitudinal associations between brain structural changes and fatigue in early MS. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 29-33.	0.9	36
107	Longitudinal associations between MRI and cognitive changes in very early MS. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 47-52.	0.9	28
108	Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. <i>Multiple Sclerosis Journal</i> , 2016, 22, 753-760.	1.4	49

#	ARTICLE	IF	CITATIONS
109	Menarche increases relapse risk in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 193-200.	1.4	50
110	Acute transverse myelitis and silent infection with <i>Mycoplasma pneumoniae</i> . <i>Journal of Pediatric Neurology</i> , 2015, 12, 145-149.	0.0	0
111	Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies. <i>International Journal of MS Care</i> , 2015, 17, 74-82.	0.4	64
112	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 897.	4.5	78
113	Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2663.	3.8	118
114	Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators. <i>Journal of Investigative Medicine</i> , 2015, 63, 729-734.	0.7	309
115	Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1374.	4.5	12
116	Longitudinally Extensive Optic Neuritis in Pediatric Patients. <i>Journal of Child Neurology</i> , 2015, 30, 120-123.	0.7	10
117	The US Network of Pediatric Multiple Sclerosis Centers. <i>Journal of Child Neurology</i> , 2015, 30, 1381-1387.	0.7	21
118	Neuropsychological correlates of multiple sclerosis across the lifespan. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1355-1364.	1.4	21
119	Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment. <i>Journal of Child Neurology</i> , 2015, 30, 1366-1370.	0.7	16
120	A randomized controlled phase II trial of riluzole in early multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 340-347.	1.7	33
121	Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 720-727.	0.9	26
122	B-cell depletion in children with neuroimmunologic conditions. <i>Neurology</i> , 2014, 83, 111-112.	1.5	5
123	Rituximab Use in Pediatric Central Demyelinating Disease. <i>Pediatric Neurology</i> , 2014, 51, 114-118.	1.0	57
124	MS and related disorders: groundbreaking news. <i>Lancet Neurology</i> , The, 2014, 13, 11-13.	4.9	7
125	Protective environmental factors for neuromyelitis optica. <i>Neurology</i> , 2014, 83, 1923-1929.	1.5	23
126	Spinal cord gray matter atrophy correlates with multiple sclerosis disability. <i>Annals of Neurology</i> , 2014, 76, 568-580.	2.8	158

#	ARTICLE	IF	CITATIONS
127	The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2014, 39, 288-293.	0.8	64
128	Patient centered decision making: Use of conjoint analysis to determine riskâ€“benefit trade-offs for preference sensitive treatment choices. <i>Journal of the Neurological Sciences</i> , 2014, 344, 80-87.	0.3	64
129	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.5	2,344
130	Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 244-252.	0.9	32
131	Neuroprotection in Multiple Sclerosis: A Therapeutic Approach. <i>CNS Drugs</i> , 2013, 27, 799-815.	2.7	18
132	Therapeutic Advances in Pediatric Multiple Sclerosis. <i>Journal of Pediatrics</i> , 2013, 163, 631-637.	0.9	4
133	EDSS variability before randomization may limit treatment discovery in primary progressive MS. <i>Multiple Sclerosis Journal</i> , 2013, 19, 775-781.	1.4	19
134	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 891-895.	1.4	32
135	Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery. <i>PLoS ONE</i> , 2013, 8, e75416.	1.1	40
136	Association of Multiple Sclerosis Susceptibility Variants and Early Attack Location in the CNS. <i>PLoS ONE</i> , 2013, 8, e75565.	1.1	14
137	Relapse severity and recovery in early pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1008-1012.	1.4	55
138	Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. <i>Annals of Neurology</i> , 2012, 72, 234-240.	2.8	220
139	Treatment Options in Multiple Sclerosis. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e22.	1.1	4
140	Early Recognition and Diagnosis of Multiple Sclerosis. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e14.	1.1	0
141	Pediatric Multiple Sclerosis. <i>Neurologic Clinics</i> , 2011, 29, 481-505.	0.8	53
142	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
143	Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 437.	4.9	101
144	Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy. <i>PLoS ONE</i> , 2011, 6, e16664.	1.1	51

#	ARTICLE	IF	CITATIONS
145	PEDIATRIC MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 181-192.	0.4	2
146	Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Annals of Neurology, 2010, 67, 618-624.	2.8	294
147	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.1	3
148	Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy, 2010, 11, 505-520.	0.9	24
149	Difference in Disease Burden and Activity in Pediatric Patients on Brain Magnetic Resonance Imaging at Time of Multiple Sclerosis Onset vs Adults. Archives of Neurology, 2009, 66, 967-71.	4.9	159
150	Clinical predictors of early second event in patients with clinically isolated syndrome. Journal of Neurology, 2009, 256, 1061-1066.	1.8	66
151	Pediatric multiple sclerosis. Current Treatment Options in Neurology, 2009, 11, 203-210.	0.7	28
152	Pediatric multiple sclerosis. Nature Reviews Neurology, 2009, 5, 621-631.	4.9	124
153	Pediatric multiple sclerosis. Current Neurology and Neuroscience Reports, 2008, 8, 434-441.	2.0	26
154	Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Annals of Neurology, 2008, 63, 395-400.	2.8	484
155	B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 676-688.	13.9	2,107
156	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology, The, 2007, 6, 773-781.	4.9	292
157	Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Annals of Neurology, 1996, 40, 846-852.	2.8	279